GO:0090100 positive regulation of transmembrane receptor protein serine/threonine kinase signaling pathway: Signaling Amplification, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0090100 describes any process that increases the rate, frequency, or extent of signaling initiated by a transmembrane receptor serine/threonine kinase upon ligand binding.
• The term covers positive regulation of TGF-beta, BMP, and related receptor serine/threonine kinase pathways, which are central to development, tissue homeostasis, and disease [5,6].
• Key positive regulators include ligand availability, receptor oligomerization, accessory proteins, and E3 ubiquitin ligases that modulate receptor turnover.
• Dysregulation of these pathways is implicated in cancer, fibrosis, and developmental disorders, making them attractive therapeutic targets [5,6].
• CRISPR knockout, point-mutation, knock-in, and overexpression models enable precise dissection of positive regulatory nodes [1,2,3].
• EDITGENE provides end-to-end CRISPR services and bioinformatics to accelerate research on GO:0090100-related mechanisms.
Description
The Gene Ontology term GO:0090100, positive regulation of transmembrane receptor protein serine/threonine kinase signaling pathway, defines any process that increases the rate, frequency, or extent of the signaling cascade triggered when a transmembrane receptor serine/threonine kinase binds its physiological ligand. This ontology term is essential for annotating gene products that amplify or sustain signaling through receptors such as TGF-beta and BMP receptors, which are critical for cell fate decisions, tissue morphogenesis, and immune regulation [5,6]. Researchers studying development, cancer, and fibrosis rely on this term to systematically classify positive regulators and to design experiments that test causality [5,6]. The pathway is frequently dysregulated in human disease, and understanding its positive regulation can reveal therapeutic vulnerabilities [5,6]. This article integrates the QuickGO definition with verified literature to provide a research-grade overview of the mechanisms, key genes, disease links, and experimental models relevant to GO:0090100.
positive regulation of transmembrane receptor protein serine/threonine kinase signaling pathway At A Glance
| GO ID | GO:0090100 |
|---|---|
| GO term | positive regulation of transmembrane receptor protein serine/threonine kinase signaling pathway |
| Ontology | biological_process |
| Synonym | positive regulation of transmembrane receptor protein serine/threonine kinase signalling pathway |
| Major function | Enhances signaling initiated by transmembrane receptor serine/threonine kinases upon ligand binding |
| Related pathways | TGF-beta, BMP, activin, and nodal signaling [5,6] |
| Key positive regulators | Ligands, receptor oligomerization, accessory proteins, E3 ubiquitin ligases |
| Disease relevance | Cancer, fibrosis, developmental disorders [5,6] |
What Is GO:0090100?
GO:0090100 refers to any biological process that enhances the signaling output of a transmembrane receptor protein serine/threonine kinase after it binds to its natural ligand. In simpler terms, it is the set of molecular events that make this type of receptor signaling stronger, longer, or more frequent. This includes mechanisms that promote ligand availability, receptor activation, downstream signal propagation, or feedback amplification, as opposed to negative regulation that dampens the pathway.
Why Is positive regulation of transmembrane receptor protein serine/threonine kinase signaling pathway Important in Cell Biology?
Positive regulation of transmembrane receptor serine/threonine kinase signaling is fundamental to organismal development and tissue homeostasis, and its dysregulation contributes to a wide range of pathologies including cancer and fibrosis [5,6]. Understanding the positive regulatory mechanisms provides insight into how cells amplify critical signals and offers potential targets for therapeutic intervention [5,6].
• Controls cell proliferation, differentiation, and apoptosis through TGF-beta and BMP pathways.
• Essential for embryonic development and organogenesis.
• Dysregulated in cancers, where enhanced signaling promotes tumor progression.
• Implicated in fibrotic diseases such as pulmonary fibrosis and liver cirrhosis.
• Modulates immune responses and inflammation.
• Provides targets for drug discovery, including receptor kinase inhibitors.
• Helps explain resistance to targeted therapies in cancer.
• Enables annotation of gene function in genomic studies.
• Facilitates cross-talk with other signaling pathways like AKT and Hippo [1,2].
• Supports development of CRISPR-based disease models [1,2,3].
What Happens During positive regulation of transmembrane receptor protein serine/threonine kinase signaling pathway?
Ligand availability and presentation
In simple terms: More ligand around means stronger signal.
Positive regulation often begins with increased production, activation, or presentation of ligands such as TGF-beta or BMPs. For example, extracellular matrix proteins can sequester or release ligands to modulate signaling intensity. In auxin signaling, ABP1/ABL3-TMK1 mediates cell-surface auxin perception to target PIN2-mediated auxin fluxes for root gravitropism, illustrating ligand-dependent positive regulation.
Receptor activation and oligomerization
In simple terms: Receptors team up to send a stronger message.
Transmembrane receptor serine/threonine kinases are activated upon ligand-induced oligomerization and transphosphorylation. Positive regulators can stabilize active receptor complexes or promote conformational changes that enhance kinase activity. For instance, DDR1 liquid-liquid phase separation counteracts the Hippo pathway to orchestrate arterial stiffening, highlighting how receptor clustering can amplify signaling.
Accessory proteins and scaffold enhancement
In simple terms: Helper proteins boost the signal.
Accessory proteins and scaffolds can enhance receptor signaling by bringing downstream effectors into proximity or protecting receptors from degradation. TMED4 targeting enhances CD8+ T cell function through the IRE1α-autophagy axis, demonstrating how accessory factors can positively regulate signaling pathways.
Post-translational modifications and ubiquitin ligases
In simple terms: Chemical tags can either strengthen or weaken the signal.
E3 ubiquitin ligases are key regulators of TGF-beta signaling, and their activity can either promote or attenuate pathway output depending on context. HECTD3 E3 ligase mediates ubiquitination of AKT-phosphorylated CMTM3 in HER2-overexpressed breast cancer cells, showing cross-talk between kinase signaling and ubiquitination.
Feedback amplification loops
In simple terms: The signal can feed back to make itself stronger.
Positive feedback loops can sustain or amplify receptor serine/threonine kinase signaling. For example, IFITM3-MET interaction drives osimertinib resistance through AKT pathway activation, illustrating how positive regulation can lead to therapeutic resistance.
Key Genes Involved in GO:0090100 positive regulation of transmembrane receptor protein serine/threonine kinase signaling pathway
The following genes and proteins are established or emerging players in the positive regulation of transmembrane receptor serine/threonine kinase signaling, based on verified literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| TGFB1 | Ligand for TGF-beta receptor; activates signaling | Cancer, fibrosis models |
| BMP2 | Ligand for BMP receptors; promotes osteogenesis | Bone development, differentiation |
| TGFBR1 | Serine/threonine kinase receptor; transduces TGF-beta signals | Knockout and point-mutation studies |
| TGFBR2 | Serine/threonine kinase receptor; binds TGF-beta | Cancer, fibrosis |
| BMPR1A | BMP receptor; activates SMAD signaling | Developmental disorders |
| BMPR2 | BMP receptor; regulates vascular homeostasis | Pulmonary arterial hypertension |
| SMAD2 | Downstream effector; positively regulated by receptor kinases | Transcriptional readout |
| SMAD3 | Downstream effector; mediates TGF-beta responses | Fibrosis, cancer |
| SMAD4 | Co-SMAD; common mediator for TGF-beta/BMP | Knockout models |
| DDR1 | Receptor tyrosine kinase; phase separation counteracts Hippo | Arterial stiffening |
| TMK1 | Auxin signaling kinase; targets PIN2 | Root gravitropism |
| ABP1 | Auxin binding protein; cell-surface signaling | Plant development |
| ABL3 | Auxin signaling component | Plant development |
| IFITM3 | Modulates MET-AKT signaling | Osimertinib resistance |
| MET | Receptor tyrosine kinase; interacts with IFITM3 | Lung cancer |
| TMED4 | Regulates IRE1α-autophagy axis | CAR T cell efficacy |
| HECTD3 | E3 ligase; ubiquitinates CMTM3 | Breast cancer |
| CMTM3 | Substrate of HECTD3; AKT-phosphorylated | HER2+ breast cancer |
How Is positive regulation of transmembrane receptor protein serine/threonine kinase signaling pathway Regulated?
Positive regulation of transmembrane receptor serine/threonine kinase signaling is itself controlled by multiple layers of regulation. E3 ubiquitin ligases can either promote or inhibit pathway activity by targeting receptors or downstream effectors for degradation or activation. For example, HECTD3-mediated ubiquitination of CMTM3 in HER2-overexpressed breast cancer cells demonstrates how post-translational modifications fine-tune signaling. Additionally, cross-talk with other pathways such as AKT and Hippo can modulate the strength and duration of receptor serine/threonine kinase signaling [1,2].
positive regulation of transmembrane receptor protein serine/threonine kinase signaling pathway and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| TGFBR1 | Cancer, fibrosis | Knockout and point-mutation cell lines |
| BMPR2 | Pulmonary arterial hypertension | Knock-in mouse models |
| IFITM3 | Osimertinib resistance in NSCLC | Overexpression in EGFR-mutant cells |
| DDR1 | Arterial stiffening | Knockout and phase-separation studies |
| HECTD3 | HER2+ breast cancer | Knockout and ubiquitination assays |
Cancer
Enhanced TGF-beta and BMP signaling is frequently observed in cancers, where it promotes epithelial-mesenchymal transition, metastasis, and immune evasion [5,6]. Positive regulators such as E3 ubiquitin ligases can amplify oncogenic signaling, and their inhibition is a therapeutic strategy. In EGFR-mutant non-small cell lung cancer, IFITM3-MET interaction drives osimertinib resistance through AKT pathway activation, highlighting how positive regulation of receptor kinase signaling contributes to drug resistance.
Fibrotic diseases
TGF-beta signaling is a master driver of fibrosis in multiple organs. Positive regulation of TGF-beta receptor serine/threonine kinase signaling exacerbates extracellular matrix deposition and tissue stiffening. DDR1 phase separation counteracts the Hippo pathway to orchestrate arterial stiffening, providing a mechanism linking positive regulation to vascular fibrosis.
Developmental disorders
BMP and TGF-beta signaling are critical for embryonic development, and mutations in pathway components cause developmental disorders. Positive regulators that enhance signaling can influence skeletal, cardiovascular, and neural development.
From positive regulation of transmembrane receptor protein serine/threonine kinase signaling pathway-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does gene X positively regulate TGF-beta signaling? | CRISPR knockout in HEK293T or HaCaT cells |
| Does point mutation Y alter receptor kinase activity? | Knock-in of mutant allele in cell lines |
| Does overexpression of gene Z enhance BMP signaling? | Doxycycline-inducible overexpression in C2C12 cells |
| Does tagged receptor localize to specific compartments? | Knock-in of fluorescent tag (e.g., GFP) in endogenous locus |
| Does gene W regulate pathway in vivo? | Conditional knockout mouse models |
| Does gene V affect drug resistance? | Overexpression in resistant cancer cell lines |
How to Study the positive regulation of transmembrane receptor protein serine/threonine kinase signaling pathway Process
| Method | What It Measures | Typical Application |
|---|---|---|
| CRISPR knockout screening | Loss-of-function effects on pathway activity | Identify positive regulators |
| RNA-seq | Transcriptional changes | Downstream target gene expression |
| Phosphoproteomics | Phosphorylation events | Receptor activation and signaling |
| Luciferase reporter assay | SMAD transcriptional activity | High-throughput screening |
| Proximity ligation assay | Protein-protein interactions | Receptor complex formation |
| Live-cell imaging | Subcellular localization and dynamics | Phase separation, trafficking |
| Ubiquitination assays | Post-translational modifications | E3 ligase function [6,8] |
| Flow cytometry | Cell surface receptor levels | Receptor turnover |
CRISPR screening
Genome-wide CRISPR knockout or activation screens can identify positive regulators of transmembrane receptor serine/threonine kinase signaling. For example, screens in cancer cells treated with TGF-beta can reveal genes whose loss reduces pathway activity.
Phosphoproteomics
Mass spectrometry-based phosphoproteomics measures changes in phosphorylation of receptor kinases and downstream effectors, providing a global view of positive regulation.
Transcriptional reporters
SMAD-responsive luciferase reporters are widely used to quantify pathway activity and identify positive regulators in high-throughput formats.
Imaging and phase separation assays
Live-cell imaging of fluorescently tagged receptors and downstream effectors can reveal clustering, phase separation, and trafficking events that contribute to positive regulation.
How CRISPR Can Be Used to Study GO:0090100 positive regulation of transmembrane receptor protein serine/threonine kinase signaling pathway
Knockout
CRISPR knockout of candidate positive regulators can determine whether a gene is required for transmembrane receptor serine/threonine kinase signaling. For example, knocking out TGFBR1 abolishes TGF-beta signaling, while knocking out E3 ligases can either enhance or reduce pathway output depending on context.
Point Mutation
Point mutations can mimic activating or inactivating lesions in receptors or downstream effectors. For instance, introducing kinase-dead mutations in TGFBR1 can confirm its role in positive regulation.
Knock-in
Knock-in of fluorescent tags or epitope tags at endogenous loci allows real-time tracking of receptor dynamics and interaction partners without overexpression artifacts.
Overexpression
Overexpression of wild-type or mutant cDNAs can test sufficiency of a gene to enhance signaling. For example, overexpressing IFITM3 in EGFR-mutant lung cancer cells drives osimertinib resistance through AKT activation.
How EDITGENE Supports positive regulation of transmembrane receptor protein serine/threonine kinase signaling pathway Research
Researchers studying positive regulation of transmembrane receptor protein serine/threonine kinase signaling pathway-related genes often need to determine whether a candidate gene is causally involved in pathway amplification, and CRISPR-based models provide the most rigorous approach for such functional validation.
Contact EDITGENE today to design your custom CRISPR model for positive regulation of transmembrane receptor protein serine/threonine kinase signaling pathway research.
Frequently Asked Questions About positive regulation of transmembrane receptor protein serine/threonine kinase signaling pathway
What is GO:0090100?
GO:0090100 is a Gene Ontology term for any process that increases the rate, frequency, or extent of signaling by a transmembrane receptor serine/threonine kinase upon ligand binding.
What genes are involved in positive regulation of transmembrane receptor serine/threonine kinase signaling?
Key genes include TGFB1, BMP2, TGFBR1, TGFBR2, BMPR1A, BMPR2, SMAD2/3/4, and modulators like E3 ubiquitin ligases [5,6].
How is this pathway dysregulated in cancer?
Enhanced TGF-beta and BMP signaling promotes tumor progression, and positive regulators can drive drug resistance, as seen with IFITM3-MET in lung cancer [1,6].
What diseases are associated with GO:0090100?
Cancer, fibrosis, and developmental disorders are linked to dysregulated positive regulation of these pathways [5,6].
How can CRISPR be used to study this pathway?
CRISPR knockout, point mutation, knock-in, and overexpression models allow functional validation of positive regulators [1,2,3].
What are the main positive regulators of TGF-beta signaling?
Ligands, receptor oligomerization, accessory proteins, and E3 ubiquitin ligases are key positive regulators.
What methods are used to measure pathway activity?
Luciferase reporters, phosphoproteomics, RNA-seq, and imaging are commonly used.
What is the role of E3 ubiquitin ligases in this pathway?
E3 ligases regulate receptor turnover and downstream effector stability, thereby modulating signaling output [6,8].
Can overexpression models be used to study positive regulation?
Yes, overexpression of candidate genes can test sufficiency to enhance signaling, as shown for IFITM3.
How does EDITGENE support research on GO:0090100?
EDITGENE provides CRISPR knockout, point mutation, knock-in, overexpression, library screening, and bioinformatics services.
Conclusion
GO:0090100 captures the positive regulation of transmembrane receptor serine/threonine kinase signaling, a process central to development and disease. Understanding its mechanisms, key genes, and regulatory layers offers opportunities for therapeutic intervention. CRISPR-based models and EDITGENE services empower researchers to dissect these pathways with precision.
References
- 1. Ibusuki R et al.. 2025. IFITM3-MET interaction drives osimertinib resistance through AKT pathway activation in EGFR-mutant non-small cell lung cancer.. Mol Cancer 24(1):272 PMID: 41152910
- 2. Liu J et al.. 2023. Liquid-Liquid Phase Separation of DDR1 Counteracts the Hippo Pathway to Orchestrate Arterial Stiffening.. Circ Res 132(1):87-105 PMID: 36475898
- 3. Rodriguez L et al.. 2025. ABP1/ABL3-TMK1 cell-surface auxin signaling targets PIN2-mediated auxin fluxes for root gravitropism.. Cell 188(22):6138-6150.e17 PMID: 41043433
- 5. Gomez-Puerto MC et al.. 2019. Bone morphogenetic protein receptor signal transduction in human disease.. J Pathol 247(1):9-20 PMID: 30246251
- 6. Sinha A et al.. 2021. E3 Ubiquitin Ligases: Key Regulators of TGFβ Signaling in Cancer Progression.. Int J Mol Sci 22(2) PMID: 33418880
- 7. Wang H et al.. 2026. Targeting TMED4 enhances CD8(+) T cell function and CAR T cell efficacy in solid tumors through the IRE1α-autophagy axis.. Sci Adv 12(24):eaee0517 PMID: 42284413
- 8. Wang J et al.. 2025. HECTD3 E3 ligase mediates ubiquitination of AKT-phosphorylated CMTM3 in HER2-overexpressed breast cancer cells.. Carcinogenesis 46(3) PMID: 40836897
